Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sara Ramquist

Neurology Dayton, OH Doctor of Osteopathy

NPI 1245762459 CMS profile 5706046

8087 Washington Village Dr Ste 120A, Dayton, OH 45458

Open in the dashboard

General payments

$8,264

360 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sara Ramquist of Dayton, OH is reported in the CMS Open Payments database as having received $8,264 across 360 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 72nd percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,481 67
2024 General $2,220 98
2023 General $1,365 57
2022 General $1,219 64
2021 General $1,066 51
2020 General $320 12
2019 General $593 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sara Ramquist
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Sara Ramquist were reported at $1,481. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Sara Ramquist Neurology median Middle half National median
2019 $593 $474 $118–$2,177 $163
2020 $320 $367 $82–$2,309 $114
2021 $1,066 $438 $104–$2,547 $132
2022 $1,219 $442 $103–$2,388 $149
2023 $1,365 $464 $119–$2,312 $160
2024 $2,220 $468 $119–$2,323 $164
2025 $1,481 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,479 71 payments
  2. UCB, Inc. $583 19 payments
  3. Genentech USA, Inc. $513 13 payments
  4. Pfizer Inc. $420 30 payments
  5. Biogen, Inc. $409 13 payments
  6. Lilly USA, LLC $326 16 payments
  7. Eisai Inc. $325 13 payments
  8. Jazz Pharmaceuticals Inc. $325 10 payments
  9. ACADIA Pharmaceuticals Inc $305 12 payments
  10. Biohaven Pharmaceuticals, Inc. $305 9 payments
  11. Other $3,273 154 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,139 358 payments
  2. Education $125 2 payments
Products named General payments · program years 2019–2025
  1. QULIPTA $956 42 payments
  2. UBRELVY $867 44 payments
  3. NURTEC ODT Primary Care $442 20 payments
  4. NURTEC ODT Pain $389 28 payments
  5. Briviact $363 13 payments
  6. OCREVUS $324 9 payments
  7. NUPLAZID $291 11 payments
  8. ZAVZPRET $261 20 payments
  9. RYTARY $240 9 payments
  10. Leqembi $230 7 payments
  11. Other $4,154 193 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 31 drugs

Part D claims

1,005

Median for Neurology: 833

Drug cost

$158,901

Median for Neurology: $202,670

Branded share of claims

16.7%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nurtec Odt Rimegepant Sulfate Brand 28 $39,344
Ubrelvy Ubrogepant Brand 24 $36,906
Briviact Brivaracetam Brand 21 $29,392
Qulipta Atogepant Brand 16 $17,513
Aimovig Autoinjector Erenumab-Aooe Brand 17 $12,813
Brilinta Ticagrelor Brand 11 $5,771
Memantine Hcl Generic 129 $5,122
Levetiracetam Generic 68 $1,537
Rivastigmine Generic 12 $1,530
Lacosamide Generic 27 $1,427

The 10 drugs with the highest cost, of 31 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$61,132

Medicare's payments for the services billed

Medicare patients

446

Average age 74

Services billed

577

255 women, 191 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 62%
Depression 39%
Ischemic heart disease 38%
Diabetes 37%
Chronic kidney disease 37%
Heart failure 29%
COPD 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 32 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $347
$347 24 —
NUPLAZID
  • ACADIA Pharmaceuticals Inc $232
$232 — —
Leqembi
  • Eisai Inc. $171
$171 — —
QULIPTA
  • AbbVie, Inc. $166
$166 16 —
NURTEC ODT
  • PFIZER INC. $149
$149 28 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 32 with Patron

Records

360 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record